“Behind the Deal”: Blackstone’s investment in Precision Medicine Group
White Paper: Developing Advanced Therapies: Considerations for Internal Versus External Manufacturing
Due to their complexity and cost, developers of cell and gene therapies face unique manufacturing hurdles. Determining the right approach to manufacturing is crucial when bringing these advanced therapeutics from clinical to commercialization.
This white paper, based on a recent webinar co-sponsored by Precision for Medicine and Informa Pharma Intelligence, features the unique expertise of Erin Harris (Editor In Chief of Cell & Gene), David Carr (Director, PRECISIONadvisors), Tony Khoury (Executive Vice President, Project Farma), Janet Lambert (CEO, Alliance for Regenerative Medicine), and Alex Karnal (Partner and Managing Director, Deerfield Management).
Webinar Video: The Great Debate — Internal vs. External Manufacturing for Advanced Therapies
Co-hosted by Endpoints Webinars, this panel discussion will address the growing industry concerns regarding manufacturing hurdles unique to cell and gene therapy. Watch as our panel of experts helps set the landscape for the current state of the advanced therapy sector and share key considerations that go into deciding whether to scale-up manufacturing internally or look to an external supplier like a CDMO.
Precision for Medicine Acquires EganLee, Expands Foothold in the Asia-Pacific (APAC) market
We are excited to announce that EganLee, an Australian-based firm providing a range of clinical trial services for the pharmaceutical, biotechnology, medical device and CRO industries has joined the Precision family! With strong, established relationships with numerous AsiaPac research sites, the acquisition of EganLee expands Precision’s clinical trial footprint in AsiaPac.
Precision Value & Health Acquires Global Omnichannel Engagement Leader, Across Health
EU-based team brings a unique omnichannel optimization platform and digital transformation capabilities to leading life-sciences companies
BETHESDA, MD—March 24, 2021—Precision Value & Health, the industry leader for commercialization services for innovative life science companies, today announced that it has acquired Across Health. Across Health is a leading global omnichannel engagement consultancy focused on providing clients an analytical and evidence-based framework for commercial strategy, execution, and resource optimization. The company’s solutions are based around its proprietary, market-leading Navigator365 product suite, which more than 40 pharmaceutical companies rely on for omnichannel planning and resource allocation. The Across Health team is already working hand-in-hand with Precision’s medical communications, creative, and data sciences teams to offer analytically driven launch and commercialization programs across the product life cycle.